Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Mariano Barbacid

Mariano Barbacid

Director, Experimental Oncology Group at CNIO

Appears in 1 story

Notable Quotes

"If everything moves at an appropriate pace, these studies could be underway within three years." — On timeline for human clinical trials

Stories

The race to drug KRAS in pancreatic cancer

New Capabilities

PNAS paper retracted April 2026 for undisclosed financial stake in Vega Oncotargets spin-off; divested from company May 5, 2026, returning shares and patent rights; paper resubmitted through standard peer review

In April 2026, daraxonrasib became the first drug to beat chemotherapy in a Phase 3 pancreatic cancer trial, cutting death risk by 60% and extending median survival from 6.7 to 13.2 months. The FDA authorized expanded access May 1; Revolution Medicines plans to file a New Drug Application and present full Phase 3 data at the ASCO Annual Meeting on May 31, 2026.

Updated 5 days ago